日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801

晚期黑色素瘤患者的缓解率和长期生存率:来自前瞻性队列研究 gem-1801 的数据

Espinosa, Enrique; Berciano-Guerrero, Miguel-Ángel; Muñoz-Couselo, Eva; Puértolas, Teresa; Manzano, José Luis; Soria, Ainara; de Miguel, Pablo Ayala; Crespo, Guillermo; Sanz, Lourdes Gutiérrez; Cerezuela-Fuentes, Pablo; de la Rosa, Carlos Aguado; Majem, Margarita; Castaño, Almudena García; Berrocal, Alfonso; Arroyo, Francisco Ramon García; de la Borbolla, María Rodríguez; Bellido, Lorena; Martínez, Javier Medina; Fernández, Luis Antonio; Carnicero, Alfonso Martin; Castro, Rafael López; Rodríguez, Aida Bujosa; Lecumberri, Mª José; Guzmán, José Carlos Villa; Balea, Begoña Campos; Rodríguez, Joaquín Fra; Bautista, Javier Valdivia; Pérez, Victor Navarro; Mujika, Karmele; Subias, Mónica Corral; Hernández, Berta; Algarra, Salvador Martín; Márquez-Rodas, Iván

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

皮肤黑色素瘤:ESMO临床实践指南(诊断、治疗和随访)

Amaral, T; Ottaviano, M; Arance, A; Blank, C; Chiarion-Sileni, V; Donia, M; Dummer, R; Garbe, C; Gershenwald, J E; Gogas, H; Guckenberger, M; Haanen, J; Hamid, O; Hauschild, A; Höller, C; Lebbé, C; Lee, R J; Long, G V; Lorigan, P; Muñoz Couselo, E; Nathan, P; Robert, C; Romano, E; Schadendorf, D; Sondak, V; Suijkerbuijk, K P M; van Akkooi, A C J; Michielin, O; Ascierto, P A

Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial

辅助性纳武利尤单抗和瑞拉利单抗治疗 III/IV 期黑色素瘤:随机 3 期 RELATIVITY-098 试验

Long, Georgina V; Garnett-Benson, Charlie; Dolfi, Sonia; Ascierto, Paolo A; Guo, Jun; Tarhini, Ahmad A; Chandra, Sunandana; Muñoz-Couselo, Eva; Del Vecchio, Michele; de Melo, Andreia Cristina; Callahan, Margaret; Gogas, Helen; Dummer, Reinhard; Schadendorf, Dirk; Koelblinger, Peter; Quereux, Gaelle; Thomas, Ioannis; Yu, Jia Xin; Fisher, Andrew; Wang, Bonnie; Djidel, Patrick; Chouzy, Armand; Semaan, Mark; Chen, Bohang; Cheong, Alicia M Y; Tawbi, Hussein A

RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE)

RP1联合Nivolumab治疗晚期抗PD-1治疗失败的黑色素瘤(IGNYTE)

Wong, Michael K; Milhem, Mohammed M; Sacco, Joseph J; Michels, Judith; In, Gino K; Muñoz Couselo, Eva; Schadendorf, Dirk; Beasley, Georgia M; Niu, Jiaxin; Chmielowski, Bartosz; Wise-Draper, Trisha M; Bowles, Tawnya Lynn; Tsai, Katy K; Lebbé, Céleste; Gaudy-Marqueste, Caroline; Middleton, Mark R; Skolariki, Aglaia; Samson, Adel; Chesney, Jason A; VanderWalde, Ari M; Zakharia, Yousef; Harrington, Kevin J; Appleton, Elizabeth; Bommareddy, Praveen K; Zhu, Junhong; Viana, Marcus; Hou, Jeannie W; Coffin, Robert S; Robert, Caroline

Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020

RELATIVITY-020 研究显示,既往和一线免疫疗法对黑色素瘤患者基线免疫生物标志物的影响以及对纳武利尤单抗和瑞拉利单抗联合治疗的肿瘤微环境调节的影响

Ascierto, Paolo A; Tang, Hao; Dolfi, Sonia; Nyakas, Marta; Marie Svane, Inge; Muñoz-Couselo, Eva; Grob, Jean Jacques; Gomez-Roca, Carlos Alberto; Chiarion-Sileni, Vanna; Peltola, Katriina; Larkin, James; Melero, Ignacio; Callahan, Margaret; Dummer, Reinhard; Djidel, Patrick; Warad, Deepti; Reusser-Wolf, Diane; Lipson, Evan J; Garnett-Benson, Charlie

Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma

纵向基因组分析优化靶向治疗:BRAFV600突变转移性黑色素瘤患者的II期LOGIC 2试验结果

Dummer, Reinhard; Sandhu, Shahneen; Miller, Wilson H Jr; Butler, Marcus O; Taylor, Matthew H; Heinzerling, Lucie; Blank, Christian U; Muñoz-Couselo, Eva; Burris, Howard A 3rd; Postow, Michael A; Chmielowski, Bartosz; Middleton, Mark R; Berking, Carola; Hassel, Jessica C; Gesierich, Anja Heike; Mauch, Cornelia; Kleha, Joseph F; Polli, Anna; Harney, Allison S; di Pietro, Alessandra; Ascierto, Paolo A

Secondary resistance to sonidegib is rare in locally advanced basal cell carcinoma

局部晚期基底细胞癌对索尼德吉的继发性耐药较为罕见。

Muñoz Couselo, Eva; Berking, Carola; Baurain, Jean François; Martelli, Serena; Arntz, Ramon; Savoia, Paola

Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study

高危早期三阴性乳腺癌患者新辅助帕博利珠单抗联合化疗疗效的分子决定因素:一项开放标签、多队列 1b 期 KEYNOTE-173 研究的探索性分析

Dent, Rebecca; Cortés, Javier; Park, Yeon Hee; Muñoz-Couselo, Eva; Kim, Sung-Bae; Sohn, Joohyuk; Im, Seock-Ah; Holgado, Esther; Foukakis, Theodoros; Kümmel, Sherko; Yearley, Jennifer; Wang, Anran; Nebozhyn, Michael; Huang, Lingkang; Cristescu, Razvan; Jelinic, Petar; Karantza, Vassiliki; Schmid, Peter

Adjuvant Immunotherapy After Resected Melanoma: Survival Outcomes, Prognostic Factors and Patterns of Relapse

黑色素瘤切除术后辅助免疫治疗:生存结果、预后因素和复发模式

Martinez-Recio, Sergio; Molina-Pérez, Maria Alejandra; Muñoz-Couselo, Eva; Sevillano-Tripero, Alberto R; Aya, Francisco; Arance, Ana; Orrillo, Mayra; Martin-Liberal, Juan; Fernandez-Morales, Luis; Lesta, Rocio; Quindós-Varela, María; Nieva, Maria; Vidal, Joana; Martinez-Perez, Daniel; Barba, Andrés; Majem, Margarita

Real-life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAF(V600)-mutant melanoma in Spain: the BECARE (GEM-2002) trial

西班牙BECARE(GEM-2002)试验:恩考拉非尼联合比美替尼治疗不可切除的晚期或转移性BRAF(V600)突变型黑色素瘤患者的真实世界证据

Soria, Ainara; Sanchez Mauriño, Pedro; Serrano Domingo, Juan José; García Galindo, Regina; Sequero, Silvia; Gutiérrez Sanz, Lourdes; Crespo, Guillermo; Díaz-Beveridge, Roberto; Puértolas, Teresa; López, Pedro; Fra Rodríguez, Joaquín; López Castro, Rafael; Aguayo, Cristina; Valdivia, Javier; Cunquero-Tomás, Alberto Jacobo; Benítez, Gretel; Ayala de Miguel, Pablo; Espinosa, Enrique; Muñoz-Couselo, Eva; Campos, Begoña; García Sánchez, Lourdes; Cerezuela-Fuentes, Pablo